CIK 0001604821 · Large accelerated filer
Natera, Inc.
Sign in to watch- Ticker
- NTRA
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 010894487
- Phone
- 650-249-9090
- Business address
- 13011 MCCALLEN PASS, BUILDING A SUITE 100, AUSTIN, TX, 78753
- Former names
- Natera, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $104,832,418
- in 28 filings, $104.8M under 10b5-1 plans
Net −$104,832,418. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Rabinowitz Matthew −$72.3M EXECUTIVE CHAIRMAN sold 9% of stake
- Sheena Jonathan −$13.8M Director sold 83% of stake
- Moshkevich Solomon −$9.5M PRESIDENT, CLINICALDIAGNOSTICS sold 21% of stake
- Chapman Steven Leonard −$5.0M CEO AND PRESIDENT sold 12% of stake
- Brophy Michael Burkes −$2.5M CHIEF FINANCIAL OFFICER sold 11% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-03 | Chapman Steven Leonard CEO AND PRESIDENT | Option exercise · Stock Option (right to buy) 10b5-1 | −150,000 | 0 | ||
| 2025-11-03 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −17,100 | $200.00 | $3.4M | 2,303,752 |
| 2025-10-31 | ROSENMAN HERM Director | Grant or award | +132 | 68,761 | ||
| 2025-10-31 | Chapman Rowan E Director | Grant or award | +128 | 6,143 | ||
| 2025-10-31 | Bertagnolli Monica Director | Grant or award | +93 | 5,221 | ||
| 2025-10-31 | Marcus Gail Boxer Director | Grant or award 10b5-1 | +121 | 5,884 | ||
| 2025-10-31 | Baynes Roy D. Director | Grant or award | +93 | 18,359 | ||
| 2025-10-31 | Williams Brinkley Ruth Director | Grant or award | +97 | 5,316 | ||
| 2025-10-31 | BOTHA ROELOF Director | Grant or award | +149 | 6,839 | ||
| 2025-10-29 | Brophy Michael Burkes CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −300 | $188.37 | $57K | 65,693 |
| 2025-10-29 | Brophy Michael Burkes CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −400 | $189.91 | $76K | 65,293 |
| 2025-10-29 | Brophy Michael Burkes CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −667 | $190.99 | $127K | 64,626 |
| 2025-10-29 | Brophy Michael Burkes CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −500 | $192.12 | $96K | 64,126 |
| 2025-10-28 | Fesko John PRESIDENT, CHIEF BUS. OFFICER | Sale 10b5-1 | −928 | $191.46 | $178K | 150,699 |
| 2025-10-28 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Sale 10b5-1 | −1,198 | $191.46 | $229K | 115,061 |
| 2025-10-28 | RABINOWITZ DANIEL SEC. AND CHIEF LEGAL OFFICER | Sale 10b5-1 | −1,058 | $191.46 | $203K | 201,699 |
| 2025-10-28 | Chapman Steven Leonard CEO AND PRESIDENT | Sale 10b5-1 | −3,680 | $191.46 | $705K | 149,840 |
| 2025-10-28 | Brophy Michael Burkes CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −1,237 | $191.46 | $237K | 67,171 |
| 2025-10-28 | Brophy Michael Burkes CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −574 | $189.90 | $109K | 66,597 |
| 2025-10-28 | Brophy Michael Burkes CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −404 | $191.51 | $77K | 66,193 |
Page 35 of 39 · 767 trades